Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. - Wikidata - awgldk - TriplyDB

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

http://www.wikidata.org/entity/Q33820610

about

What is the functional role of the thalidomide binding protein cereblon?Multiple myeloma cancer stem cells Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.Minor clone provides a reservoir for relapse in multiple myeloma Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma Differential remodeling of extracellular matrices by breast cancer initiating cells.The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.Progress in myeloma stem cells A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.Isocorydine targets the drug-resistant cellular side population through PDCD4-related apoptosis in hepatocellular carcinoma Stemness of B-cell progenitors in multiple myeloma bone marrow.Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells.Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1 Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.Biological characteristics of side population cells in a self-established human ovarian cancer cell line RARα2 expression confers myeloma stem cell features Bruceantin inhibits multiple myeloma cancer stem cell proliferation.Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels Why proteasome inhibitors cannot ERADicate multiple myeloma.

P2860

Q24635072-3ABD5294-4100-4D4C-A298-0C37969D377D Q26752365-2F798D31-03C3-4BCB-91AB-AD5532E4DCFE Q26785497-73335E81-4BB1-49D4-A1CE-CA153BF1DEC9 Q26865927-7A391BA5-EE31-4C64-AD50-4B195B69E697 Q27334339-CE52A665-9E80-427E-A740-124054DBED0D Q28534603-8BA2F383-1F20-4F0D-93A7-A47D866D9823 Q28537997-205BDDA3-0489-4BD3-BC54-0DCDFD32E2FF Q33400076-17DA08CC-E5D4-4144-97B9-08A40AC79EF1 Q33403183-586651A1-E0AB-49B5-844C-C0C1A938CDA6 Q34017354-2716A146-1748-456A-8DCF-226320ED1BDC Q34075096-9FDD78FB-B91B-4B21-B5FB-A409E21EC906 Q34147170-D4CB2517-DC88-4A59-9FE1-19B9A5B12AF6 Q34179925-BDACC939-D375-48E3-8A72-88EF975F0BE9 Q34253548-A506321F-0DD8-4D54-849B-8F2CA0055F02 Q34364560-2246FF25-D23C-4765-A477-3AD568CBEECF Q34612981-23B65010-0BC8-4F04-884B-C3D88C3FC7EF Q35128148-AD77FC2E-E40E-4ABE-9445-6F0217F83591 Q35187824-B53AB9DB-C43B-4620-8280-7873D1C20058 Q35194860-5F56A300-9CD5-4043-A178-5FDD66284C0E Q35260732-F3C2EA5D-56EE-4B5C-8B9A-C7F8193CA58F Q35544277-649D7FC7-EC0D-40E8-B77B-E96F1AD1ECBB Q35552693-FBA5C8C6-9473-445A-952C-B5C23F70CE8D Q35615252-32F7DA0C-53B1-4BE2-BD40-010CD193F3CA Q35824980-093E6E48-475D-4A75-80FA-FBAFC37004E0 Q36028412-368138DC-E4EE-42D2-B2F2-54535C1C1CB8 Q36094697-2D415C1E-84AF-4FDE-8B17-6D042E9779F7 Q36208283-78E55154-853F-4BD0-9424-8479A9DA854A Q36208638-5C9864CE-B60A-421F-853B-0F1FDAF53A66 Q36254571-86F26238-ADD6-4C74-A663-EFD700E52195 Q36327378-6E2CB8FC-4574-4A79-880D-8A7FF68842DC Q36405908-F76C104C-6F2B-4820-B2EB-2427B2D0F61A Q36474588-1E152BF7-6B92-4BB0-B081-29BCE6759813 Q36525196-6254CC06-C041-42EB-8C57-7E54867877DB Q36717999-AF647679-F880-4AFA-9FB3-A07C29FED0E8 Q36776906-DF660A08-C6EA-41AB-89BC-C07940370676 Q37001978-EF3EA475-3747-491A-99BC-D4F008C4453C Q37113087-DCCF3A6D-157F-47CA-8011-7D14B3DCCABF Q37283018-97CA9AFD-6B1A-4FED-8F95-A1569686F5FE Q37325843-6BE9D73E-619A-463F-8682-8EEA6A3CB9FE Q37393383-59937DA1-DC05-43EA-AFD6-DA04BB419713

P2860

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

http://www.wikidata.org/entity/Q33820610

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lenalidomide targets clonogeni ...... gic and clinical implications.

@ast

Lenalidomide targets clonogeni ...... gic and clinical implications.

@en

type

label

Lenalidomide targets clonogeni ...... gic and clinical implications.

@ast

Lenalidomide targets clonogeni ...... gic and clinical implications.

@en

prefLabel

Lenalidomide targets clonogeni ...... gic and clinical implications.

@ast

Lenalidomide targets clonogeni ...... gic and clinical implications.

@en

P1433

Q33820610-15147F81-2C24-4F09-A110-2CD8EFC86107

P1476

Q33820610-58A08226-AC00-4557-AAF4-4D9D668468B4

P2093

Q33820610-04B3A0CA-BBC1-4CAB-B07E-438D5AA82AAC

Q33820610-13E257CA-3C05-4C09-9095-4B1B04008A6C

Q33820610-33272BED-491A-4F8E-B876-81A7D8B19EEE

Q33820610-56EBBF03-8FBB-44D4-85E8-9506A0C49807

Q33820610-89BAA6A4-2533-4A1D-8D10-E2B4D3A849EA

Q33820610-9C22B2E8-F9FE-4D44-B0FA-01B8A8A20D0C

Q33820610-9CE21100-5F43-4843-AA90-60ED7E1C104E

Q33820610-A84DC937-3279-4D89-B520-F9EC38B88DE5

Q33820610-CA3AA00E-D8BC-49D5-871E-4B42B1D01A45

Q33820610-D05B43C5-D52F-4C2B-A6DD-F2AEF7BC147A

P2860

Q33820610-01103C21-4572-4CB9-B1DD-5D1F82612157

Q33820610-03104ED9-D4CB-4F49-8485-A1A6A2027170

Q33820610-0F77E968-BF3A-475A-A603-08FED988CE12

Q33820610-196C3589-6775-48D2-AA77-DE435BB79223

Q33820610-1C6C8BB9-0B59-4306-B6F7-EB41147AF838

Q33820610-2058F093-43DB-40D1-BCE3-8E9D49A0B171

Q33820610-244EFC65-4EF0-4293-B864-0CFF318BB6BB

Q33820610-279443B2-8C2B-450E-AA55-535F2936F64B

Q33820610-2AD0EA2F-FF3A-454A-86CB-7E8A8F03D549

Q33820610-2F1FAB58-0966-4D1B-9B1B-AE2856A9795B

P304

Q33820610-66CE3745-7220-4423-B6B8-2F6A967EB1AF

P31

Q33820610-CD67F175-146D-4826-A039-AF054674282F

P356

Q33820610-706B2717-D439-45F5-8950-970D5640A0B2

P407

Q33820610-214F8223-A5A3-4927-83D1-F4E8D74F48A1

P433

Q33820610-A305BD57-7AD2-4589-B8F0-B366766BFEDD

P478

Q33820610-DF068E60-3A94-4D28-A015-85C29F9BB8FB

P50

Q33820610-0A48FB38-FD39-4409-841D-32C8E2298FA2

Q33820610-1CFCCA1D-D1FE-41D5-8073-8D0C7D3124B6

P577

Q33820610-E1E781D0-C34A-4FA1-8C1D-AF7D212E68D1

P5875

Q33820610-6A949E9E-3159-4884-8CF5-3975AAD9968A

P698

Q33820610-7E8D2FD6-BA6C-480B-8E6A-D3CECC5C9E67

P921

Q33820610-AE4AC251-EDC1-451B-91B7-2311C8AD7C65

P932

Q33820610-99C4CCD3-E915-42B2-B6F6-B53D266C72F0

P356

BLOOD-2010-02-267344

P1433

P1476

Lenalidomide targets clonogeni ...... gic and clinical implications.

@en

P2093

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Dana Cholujova

http://www.w3.org/2001/XMLSchema#string

David Cervi

http://www.w3.org/2001/XMLSchema#string

Jacob Laubach

http://www.w3.org/2001/XMLSchema#string

Jake Delmore

http://www.w3.org/2001/XMLSchema#string

Jan Sedlak

http://www.w3.org/2001/XMLSchema#string

Jana Jakubikova

http://www.w3.org/2001/XMLSchema#string

John F Daley

http://www.w3.org/2001/XMLSchema#string

Maria Kost-Alimova

http://www.w3.org/2001/XMLSchema#string

Melissa Ooi

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of clonogenic multiple myeloma cells

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

Prospective identification of tumorigenic breast cancer cells

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Identification and expansion of human colon-cancer-initiating cells

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

Stem cells, cancer, and cancer stem cells

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

Identification of pancreatic cancer stem cells

Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells

P304

4409-4419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-02-267344

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2011-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49836339

http://www.w3.org/2001/XMLSchema#string

P698

21321360

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

P932

3099565

http://www.w3.org/2001/XMLSchema#string